# OnCo record blue-earth-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/blue-earth-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "blue-earth-therapeutics" ;
  schema:name "Blue Earth Therapeutics"@en ;
  schema:description "Blue Earth Therapeutics makes radioactive drugs that seek out a protein on prostate cancer cells (PSMA), for men whose cancer has spread and no longer responds to hormone treatment. Its lutetium-177 medicine is in a phase 2 trial, and an actinium-225 version entered its first human trial in 2026."@en ;
  schema:url <https://onco.cc/companies/blue-earth-therapeutics/>, <https://www.blueearththerapeutics.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.blueearththerapeutics.com/>, <https://www.prnewswire.com/news-releases/blue-earth-therapeutics-ltd-announces-completion-of-76-5m-series-a-financing-to-accelerate-development-of-next-generation-targeted-radioligand-therapies-302290606.html>, <https://www.blueearththerapeutics.com/pipeline>, <https://www.blueearththerapeutics.com/news> ;
  schema:addressCountry "GB" ;
  onco:related <https://onco.cc/companies/blue-earth-diagnostics/> ;
  onco:cancers <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate/> ;
  onco:sections <https://onco.cc/fronts/radiopharma/> ;
  onco:technologies <https://onco.cc/technologies/lu177-radioligand-therapy/>, <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:targets <https://onco.cc/targets/psma/> .